Question-and-Answer Session
Thank you. [Operator Instructions]. Our first question comes from Randall Stanicky. Please state your company name and you may ask your question.
Randall Stanicky - Goldman Sachs
Great. Randall Stanicky, Goldman Sachs. John and Jeff, just you referred to Protonix being exclusive for the strategic provider in your press release. I guess, just two questions there. Will that extent to an additional launch or they are just on the initial launch from Teva? And then secondly, how do you view your current supply of your generic to provide customers at the current time? And then just a follow-up kind of more big picture question for John. Do you consider or see an opportunity going forward, a lot of conjecture in the marketplace for some average launch opportunities particularly as we look at fiscal year '08? Do you envision an opportunity or do you see an opportunity for the drug wholesalers to get more aggressive in partnering with the generic companies here that bring generics to market, in other words, perhaps indemnifying some of the risks, John, damages going forward?
John H. Hammergren - Chairman, President and Chief Executive Officer
Thanks for the question. I'll see if I can answer them and I'll ask Jeff to jump in here if I miss anything. On Protonix, clearly we had a very good relationship with Teva that allowed us to be in a good position for that launch. I don't think we've described it as an exclusive relationship for the launch. So let me just be clear there. I just think we had product for our customers very early, basically the data was available, it was in our customer shelves and we feel our customers benefited by our quick action there and access to the product.
Relative to the supply of generics, we clearly try to purchase supply that matches demand in the event that we believe that demand is going to outstrip our supply, obviously, we try to get more than our fair share of the product that might be available once again benefiting our customers and benefiting our company. And on your third question, as it relates to at-risk launches, we clearly have an awareness about the fact that these can be value creating opportunities for the generic companies, if it's successful, as well as the wholesalers that are part of the distribution channel.
McKesson, at least as far as I'm concerned, will never be involved in taking on the risk associated with those decisions. I don't think we're well positioned to do that, we don't have the knowledge base nor the resources too to put ourselves in that position. That doesn't mean we want to avail ourselves of the opportunity and we won’t try to bring our tremendous customer base to the table with the generic companies, so they get access to those customers in a quick efficient way and they get an immediate update for the product.
- To read the full transcript on Seeking Alpha, click here »
